翻译(生物学)
抗原
癌症
癌症研究
生物
免疫学
医学
遗传学
基因
信使核糖核酸
作者
Chen Weller,Osnat Bartok,Christopher S. McGinnis,Heyilimu Palashati,Tiangen Chang,Dmitry B. Malko,Merav D. Shmueli,Asuteka Nagao,Déborah Hayoun,Ayaka Murayama,Yuriko Sakaguchi,Panagiotis Poulis,A. Khatib,Bracha Erlanger Avigdor,Sagi Gordon,Sapir Cohen Shvefel,Marie J. Zemanek,Morten M. Nielsen,Sigalit Boura‐Halfon,Shira Sagie
出处
期刊:Cancer Cell
[Elsevier]
日期:2025-03-29
卷期号:43 (5): 823-840.e18
被引量:10
标识
DOI:10.1016/j.ccell.2025.03.003
摘要
Aberrant peptides presented by major histocompatibility complex (MHC) molecules are targets for tumor eradication, as these peptides can be recognized as foreign by T cells. Protein synthesis in malignant cells is dysregulated, which may result in the generation and presentation of aberrant peptides that can be exploited for T cell-based therapies. To investigate the role of translational dysregulation in immunological tumor control, we disrupt translation fidelity by deleting tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) in tumor cells and characterize the downstream impact on translation fidelity and immunogenicity using immunopeptidomics, genomics, and functional assays. These analyses reveal that TYW2 knockout (KO) cells generate immunogenic out-of-frame peptides. Furthermore, Tyw2 loss increases tumor immunogenicity and leads to anti-programmed cell death 1 (PD-1) checkpoint blockade sensitivity in vivo. Importantly, reduced TYW2 expression is associated with increased response to checkpoint blockade in patients. Together, we demonstrate that defects in translation fidelity drive tumor immunogenicity and may be leveraged for cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI